Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine (Q40843303)

24 September 2017

title

Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine (English)

1 reference

24 September 2017

1 reference

1 reference

Wood MM

1

1 reference

24 September 2017

Ashby MA

series ordinal

2

1 reference

24 September 2017

Somogyi AA

series ordinal

3

1 reference

24 September 2017

Fleming BG

series ordinal

4

1 reference

24 September 2017

publication date

1 August 1998

1 reference

Journal of Pain and Symptom Management

24 September 2017

published in

1 reference

24 September 2017

volume

16

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

112-120

1 reference

Influence of heroin addiction of neuropsychological functioning

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Organic brain syndromes and opioid administration for cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Iatrogenic neurotoxicity in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

The cognitive effects of the administration of narcotic analgesics in patients with cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Driving ability in cancer patients receiving long-term morphine analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Morphine sans Morpheus

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Cognitive failure in patients with terminal cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

The assessment of pain intensity in patients with cognitive failure: A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Cognitive impairment in a patient with a normal mini-mental state examination (MMSE).

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Palliative care: an update on "terminal restlessness".

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Individual variability in the response to different opioids: report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Opioid rotation for toxicity reduction in terminal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Validity of the Trail Making Test as an Indicator of Organic Brain Damage

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

1 reference

7 January 2021

Cognitive assessment of cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Unsuspected emotional and cognitive disturbance in medical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Limits of the 'Mini-Mental State' as a screening test for dementia and delirium among hospital patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

A critique of instruments and methods to detect, diagnose, and rate delirium

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2898%2900043-8

7 January 2021

10.1016/S0885-3924(98)00043-8

Identifiers

DOI

1 reference

24 September 2017

1 reference